Rosen Law Opens Class-Action Probe into Simulations Plus Over Alleged Misleading Q3 2025 Disclosures
- Rosen Law is investigating Simulations Plus for allegedly issuing materially misleading business information harming shareholders.
- The inquiry covers investors who bought Simulations Plus securities and probes omitted material public disclosures.
- Benzinga reported Simulations Plus’ Q3 2025 sales $20.4M versus $20.9M consensus, suggesting softened demand.
Legal Probe Targets Simulations Plus’ Disclosures
Rosen Law Firm is investigating potential securities claims against Simulations Plus, Inc., alleging the company issued materially misleading business information that may have harmed shareholders. The inquiry, framed as a prospective class action on a contingency-fee basis, is open to investors who bought Simulations Plus securities and seeks to determine whether the company’s public statements about its business and outlook were inaccurate or omitted material facts. Rosen Law is offering representation without out-of-pocket fees while it evaluates whether to file a formal complaint.
The firm says its review centers on the company’s disclosures around third-quarter 2025 performance and forward-looking commentary, and whether those communications failed to accurately reflect known demand trends or sales expectations. Rosen Law is soliciting participation from prospective class members and is gathering documentation and investor testimony to assess potential misstatements and whether damages resulted from any alleged omissions. The investigation aims to establish a factual record that could support claims under federal securities laws if the firm determines litigation is warranted.
Rosen Law frames the action as part of routine investor protection work, emphasizing the procedural steps available to shareholders and the firm’s role in coordinating a unified response on behalf of affected investors. It is not yet filed litigation; Rosen Law says its inquiry could lead to a class action complaint depending on what its review uncovers. The firm encourages investors with relevant purchase dates or concerns about disclosures to come forward as it evaluates possible remedies.
Journalistic Report Flags Sales Shortfall
The inquiry follows a Benzinga report published during market hours on July 15, 2025, which details that Simulations Plus’ third-quarter 2025 sales were $20.4 million, versus a consensus estimate of $20.9 million, and references preliminary June sales guidance of $19.0 million to $20.0 million compared with a consensus figure near $22.78 million. Benzinga characterizes the company’s outlook as softening amid weaker demand trends cited in its coverage.
Rosen Law’s Credentials and Contact
Rosen Law highlights its track record in securities class actions and shareholder derivative litigation, noting prior large recoveries and industry rankings, and urges investors to select experienced counsel. Investors seeking information or to participate in the prospective action are directed to submit through Rosen Law’s online forms (https://rosenlegal.com/submit-form/?case_id=42476 or https://rosenlegal.com/submit-form/?case_id=42439), call toll-free 866-767-3653, or email [email protected].
Related Cashu News

RadNet Launches AI-Powered Reporting Pro, Enhancing Imaging Services and Financial Growth Strategy
RadNet (Ticker: RDNT) makes a notable advancement in its healthcare strategy with the recent launch of Reporting Pro, an innovative AI-powered radiology reporting platform that aims to transform the d…

HealthEquity Reports Strong Q1 Growth Amid AI Integration and Cybersecurity Challenges
HealthEquity (Ticker: HQY) reports substantial growth in its recent fiscal 2027 first-quarter results, highlighting advancements in Health Savings Accounts and total assets under management. The compa…

UFP Technologies Appoints New Leadership Team to Drive Strategic Growth and Innovation
UFP Technologies (Ticker: UFPT) experiences a pivotal moment as it undergoes significant changes in its leadership team. The company appoints Mitchell C. Rock as the new Chief Executive Officer, a mov…

Lantheus Holdings' LNTH-2513 Wins SNMMI's 2026 Image of the Year for DVT Diagnosis
Lantheus Holdings achieves significant milestone with its investigational PET imaging agent LNTH-2513 (18F-GP1), awarded SNMMI’s prestigious 2026 “Image of the Year.” The accolade highlights clinical…